Patents by Inventor Michael A. Fischbach

Michael A. Fischbach has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240024380
    Abstract: Provided are modified microorganisms, such as live recombinant commensal bacteria, that express a non-native antigen, or are surface-labeled with a non-native antigen, and methods of using the modified microorganisms to induce an antigen-specific immune response to the non-native antigen. The modified microorganism can be used to induce a regulatory T cell immune response to the heterologous antigen to treat an autoimmune disease in a subject in need thereof, or can be used to induce an effector T cell immune response to the heterologous antigen to treat an infectious disease or proliferative disease in a subject in need thereof.
    Type: Application
    Filed: December 22, 2021
    Publication date: January 25, 2024
    Inventors: Michael A. Fischbach, Kazuki Nagashima, Yiyin E. Chen, Djenet Bousbaine
  • Patent number: 11744867
    Abstract: Some embodiments relate to genetically engineered bacterial strains for modulation of levels of the bacterial metabolite 4-ethylphenol (4EP) and its sulfated form, 4-ethylphenyl sulfate (4EPS). In some embodiments, the bacteria reduce or inhibit production of 4EP or 4EPS in the gut of a subject. The bacteria can ameliorate, delay the onset, or reduce the likelihood of one or more symptoms associated with anxiety and/or autism spectrum disorder (ASD) in the subject.
    Type: Grant
    Filed: July 23, 2021
    Date of Patent: September 5, 2023
    Assignees: California Institute of Technology, The Regents of the University of California
    Inventors: Brittany D. Needham, Sarkis K. Mazmanian, Gil Sharon, Masanori Funabashi, Michael A. Fischbach, Elaine Y. Hsiao, Paul H. Patterson
  • Publication number: 20230233620
    Abstract: The present invention provides high-complexity defined gut microbial communities capable of achieving substantial engraftment and having stability following human fecal community microbial challenge and methods of producing the same. Also provided are methods of using high-complexity defined gut microbial communities for the treatment of dysbiosis or a pathological condition in an animal.
    Type: Application
    Filed: May 21, 2021
    Publication date: July 27, 2023
    Inventors: Michael A. Fischbach, Ariel R. Brumbaugh, Alice G. Cheng, Dylan Dodd, Andres Jesus Aranda-Diaz, Min Wang, Feiqiao Brian Yu, Justin L. Sonnenburg, Kerwyn C. Huang, Steve Higginbottom, Sunit Jain, Xiandong Meng, Lee Swem, Dante Ricci, Joshua J. Hamilton
  • Publication number: 20220362358
    Abstract: Provided are modified microorganisms, such as live recombinant commensal bacteria, that express a heterologous antigen, and methods of using the modified microorganisms to induce an antigen-specific immune response to the heterologous antigen. The modified microorganism can be used to induce a regulatory T cell immune response to the heterologous antigen to treat an autoimmune disease in a subject in need thereof, or can be used to induce an effector T cell immune response to the heterologous antigen to treat a proliferative disease in a subject in need thereof.
    Type: Application
    Filed: June 18, 2020
    Publication date: November 17, 2022
    Inventors: Michael A. Fischbach, Kazuki Nagashima, Yiyin E. Chen
  • Publication number: 20220096575
    Abstract: Some embodiments relate to genetically engineered bacterial strains for modulation of levels of the bacterial metabolite 4-ethylphenol (4EP) and its sulfated form, 4-ethylphenyl sulfate (4EPS). In some embodiments, the bacteria reduce or inhibit production of 4EP or 4EPS in the gut of a subject. The bacteria can ameliorate, delay the onset, or reduce the likelihood of one or more symptoms associated with anxiety and/or autism spectrum disorder (ASD) in the subject.
    Type: Application
    Filed: July 23, 2021
    Publication date: March 31, 2022
    Inventors: Brittany D. Needham, Sarkis K. Mazmanian, Gil Sharon, Masanori Funabashi, Michael A. Fischbach, Elaine Y. Hsiao, Paul H. Patterson
  • Publication number: 20220023354
    Abstract: The present invention provides high-complexity defined gut microbial communities capable of achieving substantial engraftment and having stability following human fecal community microbial challenge and methods of producing the same. Also provided are methods of using high-complexity defined gut microbial communities for the treatment of dysbiosis or a pathological condition in an animal.
    Type: Application
    Filed: November 21, 2019
    Publication date: January 27, 2022
    Inventors: Michael A. Fischbach, Ariel R. Brumbaugh, Alice G. Cheng, Dylan Dodd, Justin L. Sonnenburg, Kerwyn C. Huang, Andres Jesus Aranda-Diaz, Steve Higginbottom, Min Wang, Feiqiao Brian Yu
  • Patent number: 11224624
    Abstract: Some embodiments relate to genetically engineered bacterial strains for modulation of levels of the bacterial metabolite 4-ethylphenol (4EP) and its sulfated form, 4-ethylphenyl sulfate (4EPS). In some embodiments, the bacteria reduce or inhibit production of 4EP or 4EPS in the gut of a subject. The bacteria can ameliorate, delay the onset or reduce the likelihood of one or more symptoms associated with anxiety and/or autism spectrum disorder (ASD) in the subject.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: January 18, 2022
    Assignees: CALIFORNIA INSTITUTE OF TECHNOLOGY, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Brittany D. Needham, Sarkis K. Mazmanian, Gil Sharon, Masanori Funabashi, Michael A. Fischbach, Elaine Y. Hsiao, Paul H. Patterson
  • Patent number: 11124498
    Abstract: Disclosed herein, inter alia, are compositions for modulating protease activity and treating cancer.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: September 21, 2021
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, MASSACHUSETTS INSTITUTE OF TECHNOLOGY, PRESIDENT AND FELLOWS OF HARVARD COLLEGE
    Inventors: Michael A. Fischbach, Chun-Jun Guo, Christopher A. Voigt, Fang-Yuan Chang, Jon Clardy, Thomas Wyche
  • Publication number: 20200048227
    Abstract: Disclosed herein, inter alia, are compositions for modulating protease activity and treating cancer.
    Type: Application
    Filed: November 15, 2017
    Publication date: February 13, 2020
    Inventors: Michael A. Fischbach, Chun-Jun Guo, Christopher A. Voigt, Fang-Yuan Chang, Jon Clardy, Thomas Wyche
  • Publication number: 20190374588
    Abstract: Some embodiments relate to genetically engineered bacterial strains for modulation of levels of the bacterial metabolite 4-ethylphenol (4EP) and its sulfated form, 4-ethylphenyl sulfate (4EPS). In some embodiments, the bacteria reduce or inhibit production of 4EP or 4EPS in the gut of a subject. The bacteria can ameliorate, delay the onset or reduce the likelihood of one or more symptoms associated with anxiety and/or autism spectrum disorder (ASD) in the subject.
    Type: Application
    Filed: February 13, 2018
    Publication date: December 12, 2019
    Inventors: Brittany D. Needham, Sarkis K. Mazmanian, Gil Sharon, Masanori Funabashi, Michael A. Fischbach, Elaine Y. Hsiao, Paul H. Patterson
  • Patent number: 10227290
    Abstract: Provided herein are sphingolipid compounds that are useful for activating natural killer T cells. Also provided are methods for treating or preventing a disease or disorder that is treatable by activating the immune system by stimulating natural killer T cells. The compounds are therefore useful for treating or reducing the likelihood of occurrence of an immune diseases and disorders, such as autoimmune diseases or disorders. The compounds may also be used for treating or reducing the likelihood of occurrence of a microbial infection or for treating or reducing the likelihood of occurrence of a cancer in a subject by administering the sphingolipid compounds described herein.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: March 12, 2019
    Assignees: The Regents of the University of California, President and Fellows of Harvard College
    Inventors: Michael A. Fischbach, Jeffrey A. Bluestone, Cristina Penaranda, Laura Brown, Jon Clardy
  • Publication number: 20140377291
    Abstract: Provided herein are sphingolipid compounds that are useful for activating natural killer T cells. Also provided are methods for treating or preventing a disease or disorder that is treatable by activating the immune system by stimulating natural killer T cells. The compounds are therefore useful for treating or reducing the likelihood of occurrence of an immune diseases and disorders, such as autoimmune diseases or disorders. The compounds may also be used for treating or reducing the likelihood of occurrence of a microbial infection or for treating or reducing the likelihood of occurrence of a cancer in a subject by administering the sphingolipid compounds described herein.
    Type: Application
    Filed: February 7, 2013
    Publication date: December 25, 2014
    Inventors: Michael A. Fischbach, Jeffrey A. Bluestone, Cristina Penaranda, Laura Brown, Jon Clardy
  • Publication number: 20100048422
    Abstract: The present invention provides a method producing a modified assembly line, such as those that produce non-ribosomal peptides and polyketides. The modified assembly lines of the invention can be used to produce novel compounds with therapeutic activities. The invention also provides organisms containing modified assembly lines and libraries of modified assembly lines.
    Type: Application
    Filed: July 21, 2006
    Publication date: February 25, 2010
    Inventors: Christopher T. Walsh, Michael A. Fischbach, Jonathan R. Lai, David R. Liu, Zhe Zhou
  • Publication number: 20090097808
    Abstract: The invention relates to methods and apparatuses for guiding and emitting electromagnetic radiation from a fluid waveguide. Various methods for changing optical properties (e.g., refractive index, absorption, and fluorescence) and/or physical properties (e.g., magnetic susceptibility, electrical conductivity, and temperature) of either the waveguide core or the cladding, or both, are provided herein. In one embodiment, electromagnetic radiation is guided and/or emitted at multiple distinct wavelengths, including emission in the form of an essentially continuous band, in some cases covering at least 150 nanometers. In another embodiment, methods for splitting a waveguide core and/or the joining of at least two waveguide cores in a waveguide are provided. In yet another embodiment, the invention includes the use of thermal gradients to generate a waveguide and/or to change the properties of waveguides. Embodiments of the waveguides may be used for optical detection or spectroscopic analysis.
    Type: Application
    Filed: August 1, 2005
    Publication date: April 16, 2009
    Applicant: President and Fellows of Harvard College
    Inventors: Daniel B. Wolfe, Kateri E. Paul, Dmitri V. Vezenov, Brian T. Mayers, Richard S. Conroy, Piotr Garstecki, Michael A. Fischbach, Valentine I. Vullev, Kam Yan Tang, Mara G. Prentiss, George M. Whitesides